Efficacy of zoledronate against neuroblastoma

Surgery

Volumn 140, Issue 2, 2006, Pages 227-235

  Dickson, Paxton V ^a,b   Hamner, John B ^a,b   Cauthen, Lindsey A ^a   Ng, Catherine Y C ^a   McCarville, M Beth ^a   Davidoff, Andrew M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE ATROPHY; BONE METASTASIS; CELL COUNT; CELL CYCLE; CELL CYCLE ARREST; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; INOCULATION; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; RADIOGRAPHY; TUMOR CELL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA;

EID: 33746783759     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2006.02.004     Document Type: Article

References (24)

1. Ninane J., and Pearson A.D. Neuroblastoma. In: Andrassy R.J. (Ed). Pediatric surgical oncology (1998), W.B. Saunders, Philadelphia 175-212
2. Bukowski J.F., Dascher C.C., and Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 328 (2005) 746-750
3. Green J.R. Bisphosphonates. preclinical review. Oncologist 9 Suppl 4 (2004) 3-13
4. Roodman G.D. Biology of osteoclast activation in cancer. J Clin Oncol 19 (2001) 3562-3571
5. Senaratne S.G., and Colston K.W. Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4 (2002) 18-23
6. Oades G.M., Senaratne S.G., Clarke I.A., Kirby R.S., and Colston K.W. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170 (2003) 246-252
7. Matsumoto S., Kimura S., Segawa H., et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 (2005) 31-39
8. Xiao W., Koizumi K., Nishio M., et al. Tumor necrosis factor-alpha inhibits generation of glycophorin A+ cells by CD34+ cells. Exper Hematol 30 (2002) 1238-1247
9. Forsea A.M., Muller C., Riebeling C., Orfanos C.E., and Geilen C.C. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer 91 (2004) 803-810
10. Gober H.J., Kistowska M., Angman L., Jeno P., Mori L., and De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exper Med 197 (2003) 163-168
11. Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114 (2004) 623-633
12. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exper Ther 302 (2002) 1055-1061
13. Smith M.R. Zoledronic acid to prevent skeletal complications in cancer. Corroborating the evidence. Cancer Treat Rev 31 Suppl 3 (2005) 19-25
14. Wardley A., Davidson N., Barrett-Lee P., et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases. a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92 (2005) 1869-1876
15. Michaelson M.D., and Smith M.R. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23 (2005) 8219-8224
16. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
17. Dickson P.V., Ng C.Y., Zhou J., McCarville M.E., and Davidoff A.M. In vivo bioluminescence imaging for early detection and monitoring of disease progression in murine model of neuroblastoma. J Am Coll Surg 201 (2005) S53-S54
18. Iguchi T., Miyakawa Y., Yamamoto K., Kizaki M., and Ikeda Y. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 15 (2003) 719-727
19. Ohtsuka Y., Manabe A., Kawasaki H., et al. RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro. Blood 106 (2005) 3134-3141
20. Kang M.A., Kim K.Y., Seol J.Y., Kim K.C., and Nam M.J. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor. J Gene Med 2 (2000) 289-296
21. Michigami T., Ihara-Watanabe M., Yamazaki M., and Ozono K. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61 (2001) 1637-1644
22. Granchi D., Amato I., Battistelli L., et al. In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 111 (2004) 829-838
23. Hiraga T., Williams P.J., Ueda A., Tamura D., and Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10 (2004) 4559-4567
24. Perry C.M., and Figgitt D.P. Zoledronic acid. a review of its use in patients with advanced cancer. Drugs 64 (2004) 1197-1211